|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0428 USD | +4.99% |
|
-.--% | -4.89% |
| Apr. 18 | RepliCel Life Sciences Inc. Announces Secured Loan Agreement | CI |
| 2023 | RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
RepliCel Life Sciences Inc. filed its Annual on May 01, 2023 for the period ending Dec 31, 2022. In this report its auditor, Mao & Ying LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
| 1st Jan change | Capi. | |
|---|---|---|
| -4.89% | 2.78M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
REPLICEL LIFE SCIENCES INC. 
